Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Clinical trial NCT05672121 · RECRUITING
Trial details
- NCT number
- NCT05672121
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-06
- Primary completion
- 2026-12-28
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.